Clinical Characteristics and Risk Factors for Critically Ill Patients with Carbapenem-Resistant Klebsiella pneumoniae (CrKP): A Cohort Study from Developing Country

References

• Bengoechea José A, Joana SP. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2018;43(2):123–144.
   Web of Science ®Google Scholar
• Kazmierczak KM, De Jonge B, Stone GG, et al. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. J Antimicrob Chemother. 2020;75(5):1165–1173.32040168
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Trecarichi EM, et al. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis. 2014;20(7):1235–1236.24960464
   PubMed Web of Science ®Google Scholar
• Huang M, He P, Munir S, et al. Ecology and etiology of bacterial top rot in maize caused by Klebsiella pneumoniae KpC4. Microb Pathog. 2020;139:103906.31786257
   PubMed Web of Science ®Google Scholar
• Karlsson M, Stanton RA, Ansari U, et al. Identification of a carbapenemase-producing hypervirulent Klebsiella pneumoniae isolate in the United States. Antimicrob Agents Chemother. 2019;63(7):e00519.31061159
   PubMed Web of Science ®Google Scholar
• Arena F, Henrici De Angelis L, D’Andrea MM, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae with hypermucoviscous phenotype: a case report and literature review. Virulence. 2017;8(8):1900–1908.28276993
   PubMed Web of Science ®Google Scholar
• Zhong XS, Li YZ, Ge J, et al. Comparisons of microbiological characteristics and antibiotic resistance of Klebsiella pneumoniae isolates from urban rodents, shrews, and healthy people. BMC Microbiol. 2020;20(1):12.31937244
   PubMed Web of Science ®Google Scholar
• Niu G, Li W. Next-generation drug discovery to combat antimicrobial resistance. Trends Biochem Sci. 2019;44(11):961–972.31256981
   PubMed Web of Science ®Google Scholar
• Soares M, Dongelmans DA. Why should we not use APACHE II for performance measurement and bench marking? Rev Bras Ter Intensiva. 2017;29:268–270.28876406
   PubMedGoogle Scholar
• Lee H, Lim CW, Hong HP, et al. Efficacy of the APACHE II score at ICU discharge in predicting post-ICU mortality and ICU readmission in critically ill surgical patients. Anaesth Intensive Care. 2015;43(2):175–186.25735682
   PubMed Web of Science ®Google Scholar
• Czajka S, Ziębińska K, Marczenko K, Posmyk B, Szczepańska AJ, Krzych KJ. Validation of APACHE II, APACHE III and SAPS II scores in in-hospital and one year mortality prediction in a mixed intensive care unit in Poland: a cohort study. BMC Anesthesiol. 2020;20(1):296.33267777
   PubMed Web of Science ®Google Scholar
• Breslow MJ, Badawi O. Severity scoring in the critically ill: part 1–interpretation and accuracy of outcome prediction scoring systems. Chest. 2012;141(1):245–252.22215834
   PubMed Web of Science ®Google Scholar
• Serpa Neto A, Assunção MS, Pardini A, Silva E. Feasibility of transitioning from APACHE II to SAPS III as prognostic model in a Brazilian general intensive care unit. A retrospective study. Sao Paulo Med J. 2014;133(3):199–205.25337664
   PubMed Web of Science ®Google Scholar
• Williams JM, Greenslade JH, Chu K, Eliézer S. Severity scores in emergency department patients with presumed infection: a prospective validation study. Crit Care Med. 2016;44(3):539–547.26901543
   PubMed Web of Science ®Google Scholar
• Hashmi M, Asghar A, Shamim F, Khan FH. Validation of acute physiologic and chronic health evaluation II scoring system software developed at the Aga Khan University, Pakistan. Saudi J Anaesth. 2016;10(1):45–49.26955310
   PubMedGoogle Scholar
• Thanapaisal C, Saksaen P. A comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II score and the Trauma-Injury Severity Score (TRISS) for outcome assessment in Srinagarind Intensive Care Unit trauma patients. J Med Assoc Thai. 2012;95(Suppl 11):S25–33.23961616
   PubMedGoogle Scholar
• Moreno RP, Júnior N, Paulo A. Is APACHE II a useful tool for clinical research. Rev Bras Ter Intensiva. 2017;29(3):264–267.29044301
   PubMedGoogle Scholar
• Sun YS, Yu JL. Clinical value of blood lactate in predicting the mortality of neonatal sepsis. Chin J Contemp Ped. 2019;21(7):629–634.
   Google Scholar
• Verhaeghe M, Saïd H-I. Blood lactate and lactate kinetics as treatment and mortality markers for tissue hypoperfusion. Acta Clin Belg. 2020;75(1):1–8.30591001
   PubMed Web of Science ®Google Scholar
• Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Intensive Care Med. 2018;44(6):925–928.29675566
   PubMed Web of Science ®Google Scholar
• Vincent JL, Quintairos E, Silva A, Couto L Jr, Taccone FS. The value of blood lactate kinetics in critically ill patients: a systematic review. Crit Care. 2016;20(1):257.27520452
   PubMed Web of Science ®Google Scholar
• Jones Alan E, Shapiro Nathan I, Stephen T, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303(8):739–746.20179283
   PubMed Web of Science ®Google Scholar
• Ryoo SM, Lee J, Lee YS, et al. Lactate level versus lactate clearance for predicting mortality in patients with septic shock defined by Sepsis-3. Crit Care Med. 2018;46(6):e489–e495.29432347
   PubMed Web of Science ®Google Scholar
• Amladi AU, Abirami B, Devi SM, et al. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. Indian J Med Res. 2019;149(2):185–191.31219082
   PubMed Web of Science ®Google Scholar
• Abe R, Hagiya H, Akeda Y, Sudarsanam TD, Kandasamy S, Kekre N. Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae. BMC Res Notes. 2019;12(1):740.31706328
   PubMed Web of Science ®Google Scholar
• Abbas HA, Kadry AA, Shaker GH, Goda RM. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates. Microb Pathog. 2019;132:266–274.31096002
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu L, Fu Y, et al. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro. Ann Palliat Med. 2019;8(5):622–631.31735038
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang J, Guo Y, et al. Discovery of a potential MCR-1 inhibitor that reverses polymyxin activity against clinical mcr-1-positive Enterobacteriaceae. J Infect. 2019;78(5):364–372.30851289
   PubMed Web of Science ®Google Scholar
• Ulloa ER, Dillon N, Tsunemoto H, et al. Avibactam sensitizes carbapenem-resistant NDM-1–producing Klebsiella pneumoniae to innate immune clearance. J Infect Dis. 2019;220(3):484–493.30923801
   PubMed Web of Science ®Google Scholar
• Mikhail S, Singh NB, Mikhail RK, et al. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(8):00779–00819.
   PubMed Web of Science ®Google Scholar
• Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65.30796888
   PubMed Web of Science ®Google Scholar